ALS Therapy Development Institute (ALS TDI)

A webinar hosted by ALS TDI reviews the biotech's development of TDI 132 (Gilenya), a drug that modulates the immune system      

Posted on Friday, March 23, 2012 - 12:51, By: Amy Madsen
An overview of the development of TDI 132 for use in ALS (amyotrophic lateral sclerosis, or Lou Gehrig's disease) was the topic of a webinar hosted March 12, 2012, by the nonprofit biotech ALS Therapy Development Institute (ALS TDI) of Cambridge, Mass.

ALS research news briefs, including newly identified roles for TDP43, a new study of the TDP43 mouse, and an ongoing clinical trial of ceftriaxone

Posted on Wednesday, March 23, 2011 - 08:24, By: Margaret Wahl
TDP43 has unexpectedly extensive role Scientists have found that the protein TDP43 normally influences the synthesis of more than 1,500 other proteins, including itself. Mutations in the gene for TDP43 are a known cause of ALS, and TDP43 is depleted in the nucleus and enriched in the cytoplasm (...

At ALS TDI's 2010 Leadership Summit experts discussed the past, present and future of ALS research

Posted on Monday, November 1, 2010 - 13:44, By: Amy Madsen
ALS Therapy Development Institute (ALS TDI) CEO and Chief Scientific Officer Steve Perrin presented updates on the Institute’s drug development pipeline for ALS during the research symposium portion of a two-day ALS conference.   The MDA-supported nonprofit biotech’s 2010 Leadership Summit...